GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Great Novel Therapeutics Biotech & Medicals (ROCO:7427) » Definitions » Stock Based Compensation

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Stock Based Compensation : NT$11.29 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Great Novel Therapeutics Biotech & Medicals Stock Based Compensation?

Great Novel Therapeutics Biotech & Medicals's Stock Based Compensation for the six months ended in Dec. 2023 was NT$9.78 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 was NT$11.29 Mil.


Great Novel Therapeutics Biotech & Medicals Stock Based Compensation Historical Data

The historical data trend for Great Novel Therapeutics Biotech & Medicals's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Great Novel Therapeutics Biotech & Medicals Stock Based Compensation Chart

Great Novel Therapeutics Biotech & Medicals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Stock Based Compensation
Get a 7-Day Free Trial 0.65 1.21 3.66 4.91 11.29

Great Novel Therapeutics Biotech & Medicals Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.77 2.46 2.46 1.51 9.78

Great Novel Therapeutics Biotech & Medicals Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$11.29 Mil.


Great Novel Therapeutics Biotech & Medicals Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Great Novel Therapeutics Biotech & Medicals's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Business Description

Traded in Other Exchanges
N/A
Address
No.3, Park Street, Room WR-06, 17th Floor, Nangang District, Taipei, TWN, 11503
Great Novel Therapeutics Biotech & Medicals focuses on drug development to treat advanced cancer. The new drugs ranging from epigenetic modulators, a combination of tumor microenvironment-regulating agents, epigenetic immuno-modulators, to the protein degradation drugs targeting HDACs 1, 2, and 3, are in a developing pipeline. These drugs focus on the field of epigenetics, for the demand of clinical unmet needs in advanced and refractory cancers.

Great Novel Therapeutics Biotech & Medicals (ROCO:7427) Headlines

No Headlines